Potent inhibition of human 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 by the anti-carcinogenic and anti-inflammatory agent embelin

Biochemical Pharmacology

Volumn 86, Issue 4, 2013, Pages 476-486

  Schaible, Anja M ^a   Traber, Heidi ^a   Temml, Veronika ^b   Noha, Stefan M ^b   Filosa, Rosanna ^c   Peduto, Antonella ^c   Weinigel, Christina ^d   Barz, Dagmar ^d   Schuster, Daniela ^b   Werz, Oliver ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c UNIVERSITY OF SALERNO   (Italy)

^d JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

5 Lipoxygenase; Arachidonic acid; Embelin; Inflammation; Microsomal prostaglandin E2 synthase 1

Indexed keywords

1,1 DIPHENYL 2 PICRYLHYDRAZYL; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 1; EMBELIN; ICOSANOID; MICROSOMAL PROSTAGLANDIN E2 SYNTHASE 1; PHOSPHOLIPASE A2; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; TRITON X 100; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; IC 50; INFLAMMATION; MOLECULAR DOCKING; MONOCYTE; NEOPLASM; NEUTROPHIL; PRIORITY JOURNAL;

EID: 84884902697     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.04.015     Document Type: Article

References (57)

1. Thippeswamy BS, Mahendran S, Biradar MI, Raj P, Srivastava K, Badami S, et al. Protective effect of embelin against acetic acid induced ulcerative colitis in rats. Eur J Pharmacol 2011;654:100-5.
2. Kumar GK, Dhamotharan R, Kulkarni NM, Honnegowda S, Murugesan S. Embelin ameliorates dextran sodium sulfate-induced colitis in mice. Int Immunopharmacol 2011;11:724-31.
3. Kalyan Kumar G, Dhamotharan R, Kulkarni NM, Mahat MYA, Gunasekaran J, Ashfaque M. Embelin reduces cutaneous TNF-a level and ameliorates skin edema in acute and chronic model of skin inflammation in mice. Eur J Pharmacol 2011;662:63-9.
4. Mahendran S, Badami S, Ravi S, Thippeswamy BS, Veerapur VP. Synthesis and evaluation of analgesic and anti-inflammatory activities of most active free radical scavenging derivatives of embelin - a structure-activity relationship. Chem Pharm Bull (Tokyo) 2011;59:913-9.
5. Mahendran S, Badami S, Ravi S, Thippeswamy B, Veerapur V. Antioxidant, analgesic and anti-inflammatory properties of new ninhydrin adduct of embelin. Pharm Chem J 2011;45:547-51.
6. Dai Y, Qiao L, Chan KW, Yang M, Ye J, Ma J, et al. Peroxisome proliferatoractivated receptor-g contributes to the inhibitory effects of embelin on colon carcinogenesis. Cancer Res 2009;69:4776-83.
7. Dai Y, Desano J, Qu Y, Tang W, Meng Y, Lawrence TS, et al. Natural IAP inhibitor Embelin enhances therapeutic efficacy of ionizing radiation in prostate cancer. Am J Cancer Res 2011;1:128-43.
8. Mahendran S, Thippeswamy BS, Veerapur VP, Badami S. Anticonvulsant activity of embelin isolated from Embelia ribes. Phytomedicine 2011;18:186-8.
9. Thippeswamy B, Nagakannan P, Shivasharan B, Mahendran S, Veerapur V, Badami S. Protective effect of embelin from Embelia ribes Burm. against transient global ischemia-induced brain damage in rats. Neurotox Res 2011;20:379-86.
10. Reuter S, Prasad S, Phromnoi K, Kannappan R, Yadav VR, Aggarwal BB. Embelin suppresses osteoclastogenesis induced by receptor activator of NF-kB ligand and tumor cells in vitro through inhibition of the NF-kB cell signaling pathway. Mol Cancer Res 2010;8:1425-36.
11. Ahn KS, Sethi G, Aggarwal BB. Embelin, an inhibitor of X chromosome-linked inhibitor-of-apoptosis protein, blocks nuclear factor-kB (NF-kB) signaling pathway leading to suppression of NF-kB-regulated antiapoptotic and metastatic gene products. Mol Pharmacol 2007;71:209-19. (Pubitemid 46020991)
12. Nikolovska-Coleska Z, Xu L, Hu Z, Tomita Y, Li P, Roller PP, et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine threedimensional structure database. J Med Chem 2004;47:2430-40. (Pubitemid 38580082)
13. Peters-Golden M, Henderson WR. Leukotrienes. New Engl J Med 2007;357: 1841-54.
14. Radmark O, Werz O, Steinhilber D, Samuelsson B. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 2007;32:332-41. (Pubitemid 47021417)
15. Funk CD. Prostaglandins and leukotrienes advances in eicosanoid biology. Science 2001;294:1871-5. (Pubitemid 33101574)
16. Wang D, DuBois RN. Eicosanoids and cancer. Nat Rev Cancer 2010;10:181-93.
17. Koeberle A, Werz O. Inhibitors of the microsomal prostaglandin E(2) synthase- 1 as alternative to non steroidal anti-inflammatory drugs (NSAIDs) - a critical review. Curr Med Chem 2009;16:4274-96.
18. Radmark O, Samuelsson B. Microsomal prostaglandin E synthase-1 and 5- lipoxygenase: potential drug targets in cancer. J Int Med 2010;268:5-14.
19. Dorn HW, Warren WH, Bullock JL. Certain derivatives of the ethers of hydroxyhydroquinone. J Am Chem Soc 1939;61:144-7.
20. Fischer L, Szellas D, Radmark O, Steinhilber D, Werz O. Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox- type inhibitors. FASEB J 2003;17:949-51.
21. Werz O, Klemm J, Samuelsson B, Radmark O. Phorbol ester up-regulates capacities for nuclear translocation and phosphorylation of 5-lipoxygenase in Mono Mac 6 cells and human polymorphonuclear leukocytes. Blood 2001;97: 2487-95. (Pubitemid 32291497)
22. Pergola C, Dodt G, Rossi A, Neunhoeffer E, Lawrenz B, Northoff H, et al. ERKmediated regulation of leukotriene biosynthesis by androgens: a molecular basis for gender differences in inflammation and asthma. Proc Natl Acad Sci USA 2008;105:19881-86.
23. Koeberle A, Zettl H, Greiner C, Wurglics M, Schubert-Zsilavecz M, Werz O. Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. J Med Chem 2008;51:8068-76.
24. Albert D, Zündorf I, Dingermann T, Müller WE, Steinhilber D, Werz O. Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol 2002;64:1767-75. (Pubitemid 35355728)
25. Koeberle A, Siemoneit U, Buhring U, Northoff H, Laufer S, Albrecht W, et al. Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. J Pharmacol Exp Ther 2008;326:975-82.
26. Hoffmann M, Lopez JJ, Pergola C, Feisst C, Pawelczik S, Jakobsson PJ, et al. Hyperforin induces Ca(2+)-independent arachidonic acid release in human platelets by facilitating cytosolic phospholipase A(2) activation through select phospholipid interactions. Biochim Biophys Acta 2010;1801:462-72.
27. Bauer J, Koeberle A, Dehm F, Pollastro F, Appendino G, Northoff H, et al. Arzanol, a prenylated heterodimeric phloroglucinyl pyrone, inhibits eicosanoid biosynthesis and exhibits anti-inflammatory efficacy in vivo. Biochem Pharmacol 2011;81:259-68.
28. GOLD 5.01, The Cambridge Crystallographic Data Centre, Cambridge, UK, 2012, www.ccdc.cam.ac.uk.
29. OMEGA, version 2.2.1; OpenEye Scientific Software, Santa Fe, NM, USA, 2007, www.eyesopen.com.
30. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucl Acid Res 2000;28:235-42. (Pubitemid 30047768)
31. Gilbert NC, Bartlett SG, Waight MT, Neau DB, Boeglin WE, Brash AR, et al. The structure of human 5-lipoxygenase. Science 2011;331:217-9.
32. Maestro, version 9.2.112, Schrodinger, LLC, New York, NY, 2011, www.schrodinger. com.
33. Jegerschöld C, Pawelzik S-C, Purhonen P, Bhakat P, Gheorghe KR, Gyobu N, et al. Structural basis for induced formation of the inflammatory mediator prostaglandin E2. Proc Natl Acad Sci USA 2008;105:11110-15.
34. Chen K-C, Sun M-F, Yang S-C, Chang S-S, Chen H-Y, Tsai F-J, et al. Investigation into potent inflammation inhibitors from traditional Chinese medicine. Chem Biol Drug Design 2011;78:679-88.
35. Park S-J, Han S-G, Ahsan HM, Lee K, Lee JY, Shin J-S, et al. Identification of novel mPGES-1 inhibitors through screening of a chemical library. Bioorg Med Chem Lett 2012;22:7335-9.
36. Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL, et al. 5-Lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 1991;256:929-37.
37. Wiegard A, Hanekamp W, Griessbach K, Fabian J, Lehr M. Pyrrole alkanoic acid derivatives as nuisance inhibitors of microsomal prostaglandin E2 synthase-1. Eur J Med Chem 2012;48:153-63.
38. Poeckel D, Niedermeyer TH, Pham HT, Mikolasch A, Mundt S, Lindequist U, et al. Inhibition of human 5-lipoxygenase and anti-neoplastic effects by 2- amino-1,4-benzoquinones. Med Chem 2006;2:591-5. (Pubitemid 44752493)
39. Reddy KV, Hammarberg T, Radmark O. Mg2+ activates 5-lipoxygenase in vitro: dependency on concentrations of phosphatidylcholine and arachidonic acid. Biochemistry 2000;39:1840-8. (Pubitemid 30108977)
40. Feisst C, Pergola C, Rakonjac M, Rossi A, Koeberle A, Dodt G, et al. Hyperforin is a novel type of 5-lipoxygenase inhibitor with high efficacy in vivo. Cell Mol Life Sci 2009;66:2759-71.
41. Koeberle A, Siemoneit U, Bühring U, Northoff H, Laufer S, Albrecht W, et al. Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. J Pharmacol Exp Ther 2008;326:975-82.
42. Joshi R, Kamat JP, Mukherjee T. Free radical scavenging reactions and antioxidant activity of embelin: biochemical and pulse radiolytic studies. Chem Biol Int 2007;167:125-34. (Pubitemid 46498018)
43. Pergola C, Werz O. 5-Lipoxygenase inhibitors: a review of recent developments and patents. Expert Opin Ther Pat 2010;20:355-75.
44. Rani VU, Jyothi G, Rao GN, Sailaga BBV. Chemical speciation of binary complexes of embelin with some biologically important metal ions. Acta Chim Slov 2010;57:916-21.
45. Wisniewska JM, Rodl CB, Kahnt AS, Buscato E, Ulrich S, Tanrikulu Y, et al. Molecular characterization of EP6 - a novel imidazo[1,2-a]pyridine based direct 5-lipoxygenase inhibitor. Biochem Pharmacol 2012;83:228-40.
46. Yoshimoto T, Yokoyama C, Ochi K, Yamamoto S, Maki Y, Ashida Y, et al. 2,3,5- Trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone (AA861), a selective inhibitor of the 5-lipoxygenase reaction and the biosynthesis of slow-reacting substance of anaphylaxis. Biochim Biophys Acta 1982;713: 470-3. (Pubitemid 13222960)
47. Werz O. Inhibition of 5-lipoxygenase product synthesis by natural compounds of plant origin. Planta Med 2007;73:1331-57. (Pubitemid 350084452)
48. Ohkawa S, Terao T, Murakami M, Matsumoto T, Goto G. Reduction of 2,3,5- trimethyl-6-(3-pyridylmethyl)-1,4-benzoquinone by PB-3c cells and biological activity of its hydroquinone. Chem Pharm Bull (Tokyo) 1991;39: 917-21.
49. Skrzypczak-Jankun E, Bross RA, Carroll RT, Dunham WR, Funk Jr MO. Threedimensional structure of a purple lipoxygenase. J Am Chem Soc 2001;123: 10814-20.
50. Gilbert NC, Rui Z, Neau DB, Waight MT, Bartlett SG, Boeglin WE, et al. Conversion of human 5-lipoxygenase to a 15-lipoxygenase by a point mutation to mimic phosphorylation at Serine-663. FASEB J 2012;26:3222-9.
51. De Simone R, Chini MG, Bruno I, Riccio R, Mueller D, Werz O, et al. Structurebased discovery of inhibitors of microsomal prostaglandin E2 synthase-1, 5- lipoxygenase and 5-lipoxygenase-activating protein: promising hits for the development of new anti-inflammatory agents. J Med Chem 2011;54: 1565-75.
52. Elkady M, Niess R, Schaible AM, Bauer J, Luderer S, Ambrosi G, et al. Modified acidic nonsteroidal anti-inflammatory drugs as dual inhibitors of mPGES-1 and 5-LOX. J Med Chem 2012;55:8958-62.
53. Liedtke AJ, Keck PR, Lehmann F, Koeberle A, Werz O, Laufer SA. Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX). J Med Chem 2009;52: 4968-72.
54. Landa P, Kutil Z, Temml V, Vuorinen A, Malik J, Dvorakova M, et al. Redox and non-redox mechanism of in vitro cyclooxygenase inhibition by natural quinones. Planta Med 2012;78:326-33.
55. Kim SW, Kim SM, Bae H, Nam D, Lee JH, Lee SG, et al. Embelin inhibits growth and induces apoptosis through the suppression of Akt/mTOR/S6K1 signaling cascades. Prostate 2013;73:296-305.
56. Heo JY, Kim HJ, Kim S-M, Park K-R, Park S-Y, Kim SW, et al. Embelin suppresses STAT3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase PTEN. Cancer Lett 2011;308:71-80.
57. Werz O, Steinhilber D. Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol Ther 2006;112:701-18. (Pubitemid 44592614)